Peptide YY (PYY 3-36)
Overview
Peptide YY 3-36 is a 34-amino acid endogenous peptide hormone secreted by L-cells in the distal small intestine and colon in response to nutrient intake. It acts primarily on the Y2 receptor in the hypothalamus to reduce appetite and slow gastric emptying, functioning as part of the ileal brake mechanism.
Mechanism of Action
The therapeutic rationale for exogenous PYY 3-36 administration centers on treatment of obesity through appetite suppression. Circulating levels are reduced in obesity and elevated after bariatric surgery.
Research Summary & Key Findings
Early proof-of-concept studies demonstrated that intravenous PYY 3-36 infusion reduced food intake in both lean and obese subjects. Clinical development of intranasal formulations has been pursued to improve delivery, but phase II trials showed modest weight loss and challenges with patient adherence and tolerability. No PYY-based therapeutic has advanced beyond mid-stage trials, though interest persists in combination approaches with other gut hormones.
Clinical Status
Peptide YY (PYY 3-36) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed — "Peptide YY"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Peptide YY"
Registered interventional and observational studies, including status and phase.
- PubChem — "Peptide YY"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Gastrointestinal
Octreotide (Sandostatin)
FDA ApprovedA synthetic octapeptide analog of somatostatin with a substantially longer half-life (90 minutes IV, 6 hours subcutaneou...
View detailsLanreotide (Somatuline Depot)
FDA ApprovedA synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and moderate affinity for SSTR5 receptors. L...
View detailsPasireotide (Signifor)
FDA ApprovedA multireceptor-targeted somatostatin analog with high binding affinity for SSTR1, SSTR2, SSTR3, and SSTR5, particularly...
View detailsPlecanatide (Trulance)
FDA ApprovedA synthetic 16-amino acid peptide structurally related to uroguanylin, an endogenous intestinal peptide that regulates f...
View detailsStart Your Consultation
Get an AI-proposed Peptide YY (PYY 3-36) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Peptide YY (PYY 3-36).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.